{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:11:26Z","timestamp":1767064286052},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T00:00:00Z","timestamp":1271116800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2407-10-137","type":"journal-article","created":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T18:14:26Z","timestamp":1271182466000},"source":"Crossref","is-referenced-by-count":9,"title":["In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer"],"prefix":"10.1186","volume":"10","author":[{"given":"Martin","family":"P\u00f6lcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Rudlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus","family":"Friedrichs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"Mielich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"H\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Wolfgarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walther","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"issue":"Suppl 1","key":"1936_CR1","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"95","author":"AP Heintz","year":"2006","unstructured":"Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006, 95 (Suppl 1): S161-192. 10.1016\/S0020-7292(06)60033-7.","journal-title":"Int J Gynaecol Obstet"},{"issue":"10","key":"1936_CR2","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1002\/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#","volume":"92","author":"W Kuhn","year":"2001","unstructured":"Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H: Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer. 2001, 92 (10): 2585-2591. 10.1002\/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#.","journal-title":"Cancer"},{"issue":"4","key":"1936_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1586\/14737140.4.4.639","volume":"4","author":"TW Park","year":"2004","unstructured":"Park TW, Kuhn WC: Neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther. 2004, 4 (4): 639-647. 10.1586\/14737140.4.4.639.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"1936_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3892\/or_00000479","volume":"22","author":"M Polcher","year":"2009","unstructured":"Polcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, Hoss C, Leutner C, Braun M, Mobus V, et al: Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - a prospective multicenter phase II trial (PRIMOVAR). Oncol Rep. 2009, 22 (3): 605-613. 10.3892\/or_00000479.","journal-title":"Oncol Rep"},{"key":"1936_CR5","volume-title":"12th Biennial Meeting, International Gynecological Cancer Society (IGCS): 2008; Bangkok","author":"IB Vergote","year":"2008","unstructured":"Vergote IB, Trop\u00e9 CG, Amant F, Kristensen GB, Sardi JE: EORTC-GCG\/NCIC-CTG Randomised Trial Comparing Primary Debulking Surgery With Neoadjuvant Chemotherapy in Stage IIIC-IV Ovarian, Fallopian Tube and Peritoneal Cancer (OVCA). 12th Biennial Meeting, International Gynecological Cancer Society (IGCS): 2008; Bangkok. 2008"},{"issue":"1","key":"1936_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016\/S0092-8674(00)81683-9.","journal-title":"Cell"},{"issue":"21","key":"1936_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971, 285 (21): 1182-1186. 10.1056\/NEJM197111182852108.","journal-title":"N Engl J Med"},{"issue":"1","key":"1936_CR8","first-page":"9","volume":"147","author":"N Weidner","year":"1995","unstructured":"Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995, 147 (1): 9-19.","journal-title":"Am J Pathol"},{"issue":"3","key":"1936_CR9","first-page":"587","volume":"5","author":"AA Alvarez","year":"1999","unstructured":"Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC: The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res. 1999, 5 (3): 587-591.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1936_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6","volume":"69","author":"G Gasparini","year":"1996","unstructured":"Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, Radaelli U, Di Bacco A, Guglielmi RB, Bevilacqua P: Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer. 1996, 69 (3): 205-211. 10.1002\/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6.","journal-title":"Int J Cancer"},{"issue":"4","key":"1936_CR11","first-page":"425","volume":"24","author":"A Labiche","year":"2009","unstructured":"Labiche A, Elie N, Herlin P, Denoux Y, Crouet H, Heutte N, Joly F, Heron JF, Gauduchon P, Henry-Amar M: Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma. Histol Histopathol. 2009, 24 (4): 425-435.","journal-title":"Histol Histopathol"},{"issue":"5","key":"1936_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1048-891X.2004.014514.x","volume":"14","author":"MR Raspollini","year":"2004","unstructured":"Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Taddei GL: Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer. 2004, 14 (5): 815-823. 10.1111\/j.1048-891X.2004.014514.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"3-4","key":"1936_CR13","first-page":"129","volume":"60","author":"B Rossochacka-Rostalska","year":"2007","unstructured":"Rossochacka-Rostalska B, Gisterek IJ, Suder E, Szelachowska JK, Matkowski RA, Lacko A, Kornafel JA: [Prognostic significance of microvessel density in ovarian cancer]. Wiad Lek. 2007, 60 (3-4): 129-137.","journal-title":"Wiad Lek"},{"issue":"3","key":"1936_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ygyno.2008.11.030","volume":"112","author":"JM Rubatt","year":"2009","unstructured":"Rubatt JM, Darcy KM, Hutson A, Bean SM, Havrilesky LJ, Grace LA, Berchuck A, Secord AA: Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. Gynecol Oncol. 2009, 112 (3): 469-474. 10.1016\/j.ygyno.2008.11.030.","journal-title":"Gynecol Oncol"},{"issue":"5B","key":"1936_CR15","first-page":"3925","volume":"26","author":"A Gadducci","year":"2006","unstructured":"Gadducci A, Ferrero A, Cosio S, Zola P, Viacava P, Dompe D, Fanelli G, Ravarino N, Motta M, Cristofani R, et al: Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res. 2006, 26 (5B): 3925-3932.","journal-title":"Anticancer Res"},{"issue":"1-2","key":"1936_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0304-3835(99)00005-1","volume":"138","author":"A Obermair","year":"1999","unstructured":"Obermair A, Wasicky R, Kaider A, Preyer O, Losch A, Leodolter S, Kolbl H: Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett. 1999, 138 (1-2): 175-182. 10.1016\/S0304-3835(99)00005-1.","journal-title":"Cancer Lett"},{"issue":"1","key":"1936_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0304-3835(01)00754-6","volume":"176","author":"S Ogawa","year":"2002","unstructured":"Ogawa S, Kaku T, Kobayashi H, Hirakawa T, Ohishi Y, Kinukawa N, Nakano H: Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett. 2002, 176 (1): 111-118. 10.1016\/S0304-3835(01)00754-6.","journal-title":"Cancer Lett"},{"key":"1936_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1749-6632.1994.tb12041.x","volume":"714","author":"PJ Newman","year":"1994","unstructured":"Newman PJ: The role of PECAM-1 in vascular cell biology. Ann N Y Acad Sci. 1994, 714: 165-174. 10.1111\/j.1749-6632.1994.tb12041.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"42","key":"1936_CR19","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.1038\/sj.onc.1206813","volume":"22","author":"E Fonsatti","year":"2003","unstructured":"Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M: Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene. 2003, 22 (42): 6557-6563. 10.1038\/sj.onc.1206813.","journal-title":"Oncogene"},{"issue":"1","key":"1936_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V87.1.1.1","volume":"87","author":"DS Krause","year":"1996","unstructured":"Krause DS, Fackler MJ, Civin CI, May WS: CD34: structure, biology, and clinical utility. Blood. 1996, 87 (1): 1-13.","journal-title":"Blood"},{"issue":"9","key":"1936_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1097\/01.LAB.0000028824.03032.AB","volume":"82","author":"HJ Kahn","year":"2002","unstructured":"Kahn HJ, Marks A: A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002, 82 (9): 1255-1257.","journal-title":"Lab Invest"},{"issue":"4","key":"1936_CR22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2001.19.4.1195","volume":"19","author":"KD Miller","year":"2001","unstructured":"Miller KD, Sweeney CJ, Sledge GW: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001, 19 (4): 1195-1206.","journal-title":"J Clin Oncol"},{"key":"1936_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3892\/or_00000479","volume":"22","author":"M P\u00f6lcher","year":"2009","unstructured":"P\u00f6lcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K: Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Advanced Ovarian Cancer - a Prospective Multicenter Phase 2 Trial (PRIMOVAR). Oncol Rep. 2009, 22: 605-613. 10.3892\/or_00000479.","journal-title":"Oncol Rep"},{"issue":"2","key":"1936_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF00666038","volume":"36","author":"N Weidner","year":"1995","unstructured":"Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995, 36 (2): 169-180. 10.1007\/BF00666038.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1936_CR25","first-page":"81","volume":"57","author":"N Klauber","year":"1997","unstructured":"Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997, 57 (1): 81-86.","journal-title":"Cancer Res"},{"issue":"13","key":"1936_CR26","first-page":"1191","volume":"1","author":"KA Hotchkiss","year":"2002","unstructured":"Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL: Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther. 2002, 1 (13): 1191-1200.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1936_CR27","first-page":"3369","volume":"61","author":"CJ Sweeney","year":"2001","unstructured":"Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001, 61 (8): 3369-3372.","journal-title":"Cancer Res"},{"issue":"1","key":"1936_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ijc.10907","volume":"104","author":"DS Grant","year":"2003","unstructured":"Grant DS, Williams TL, Zahaczewsky M, Dicker AP: Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer. 2003, 104 (1): 121-129. 10.1002\/ijc.10907.","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"1936_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1525-1438.2006.00307.x","volume":"16","author":"C Rudlowski","year":"2006","unstructured":"Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S, Schroeder W: Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 2006, 16 (Suppl 1): 183-189. 10.1111\/j.1525-1438.2006.00307.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1936_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.critrevonc.2008.06.009","volume":"69","author":"B Dome","year":"2009","unstructured":"Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, Lang G, Dome P, Bogos K, Tovari J: Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. Crit Rev Oncol Hematol. 2009, 69 (2): 108-124. 10.1016\/j.critrevonc.2008.06.009.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"1936_CR31","doi-asserted-by":"publisher","first-page":"C572","DOI":"10.1152\/ajpcell.00330.2003","volume":"287","author":"T Asahara","year":"2004","unstructured":"Asahara T, Kawamoto A: Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol. 2004, 287 (3): C572-579. 10.1152\/ajpcell.00330.2003.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"1936_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","volume":"14","author":"Y Shaked","year":"2008","unstructured":"Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, et al: Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008, 14 (3): 263-273. 10.1016\/j.ccr.2008.08.001.","journal-title":"Cancer Cell"},{"issue":"15","key":"1936_CR33","first-page":"4342","volume":"63","author":"F Bertolini","year":"2003","unstructured":"Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003, 63 (15): 4342-4346.","journal-title":"Cancer Res"},{"issue":"6","key":"1936_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004, 4 (6): 423-436. 10.1038\/nrc1369.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1936_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008, 26 (1): 76-82. 10.1200\/JCO.2007.12.1939.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1936_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1158\/0008-5472.CAN-06-3282","volume":"67","author":"AA Kamat","year":"2007","unstructured":"Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, et al: Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007, 67 (1): 281-288. 10.1158\/0008-5472.CAN-06-3282.","journal-title":"Cancer Res"},{"issue":"1-2","key":"1936_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1023\/A:1026500431505","volume":"19","author":"M Schirner","year":"2000","unstructured":"Schirner M: Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev. 2000, 19 (1-2): 67-73. 10.1023\/A:1026500431505.","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"1936_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrc1971","volume":"6","author":"F Bertolini","year":"2006","unstructured":"Bertolini F, Shaked Y, Mancuso P, Kerbel RS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer. 2006, 6 (11): 835-845. 10.1038\/nrc1971.","journal-title":"Nat Rev Cancer"},{"issue":"29","key":"1936_CR39","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1038\/sj.onc.1204487","volume":"20","author":"P Giannakakou","year":"2001","unstructured":"Giannakakou P, Robey R, Fojo T, Blagosklonny MV: Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1\/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001, 20 (29): 3806-3813. 10.1038\/sj.onc.1204487.","journal-title":"Oncogene"},{"issue":"6","key":"1936_CR40","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/0008-5472.CAN-04-2624","volume":"65","author":"E Pasquier","year":"2005","unstructured":"Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, Braguer D: Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res. 2005, 65 (6): 2433-2440. 10.1158\/0008-5472.CAN-04-2624.","journal-title":"Cancer Res"},{"issue":"9698","key":"1936_CR41","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009, 374 (9698): 1331-1338. 10.1016\/S0140-6736(09)61157-0.","journal-title":"Lancet"},{"issue":"4","key":"1936_CR42","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1200\/JCO.2004.03.017","volume":"22","author":"G Bolis","year":"2004","unstructured":"Bolis G, Scarfone G, Polverino G, Raspagliesi F, Tateo S, Richiardi G, Melpignano M, Franchi M, Mangili G, Presti M, et al: Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol. 2004, 22 (4): 686-690. 10.1200\/JCO.2004.03.017.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1936_CR43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","volume":"18","author":"FM Muggia","year":"2000","unstructured":"Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000, 18 (1): 106-115.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1936_CR44","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2003.10.082","volume":"21","author":"GA Omura","year":"2003","unstructured":"Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, Arbuck SG: Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 2003, 21 (15): 2843-2848. 10.1200\/JCO.2003.10.082.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1936_CR45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrc1650","volume":"5","author":"JJ Kim","year":"2005","unstructured":"Kim JJ, Tannock IF: Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005, 5 (7): 516-525. 10.1038\/nrc1650.","journal-title":"Nat Rev Cancer"},{"issue":"33","key":"1936_CR46","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","volume":"25","author":"RA Burger","year":"2007","unstructured":"Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007, 25 (33): 5165-5171. 10.1200\/JCO.2007.11.5345.","journal-title":"J Clin Oncol"},{"issue":"33","key":"1936_CR47","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","volume":"25","author":"SA Cannistra","year":"2007","unstructured":"Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007, 25 (33): 5180-5186. 10.1200\/JCO.2007.12.0782.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1936_CR48","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009, 15 (3): 232-239. 10.1016\/j.ccr.2009.01.021.","journal-title":"Cancer Cell"},{"issue":"3","key":"1936_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009, 15 (3): 220-231. 10.1016\/j.ccr.2009.01.027.","journal-title":"Cancer Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-137\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T18:26:03Z","timestamp":1591208763000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,13]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1936"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-137","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,13]]},"article-number":"137"}}